Skip to main content

Table 6 Predictors of pneumonia in RA patients by the Cox-hazard model (Multivariate analysis)

From: The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial

  Hazard ratio P value 95% CI
Demographics
 Age (years) 1.039 0.068 0.997–1.083
 Gender, male 0.580 0.317 0.200–1.686
 Smoking history 1.247 0.670 0.452–3.443
Laboratory data
 CRP (mg/dl) 1.384 0.268 0.779–2.459
 Serum albumin (g/dl) 0.917 0.877 0.305–2.758
 Serum creatinine (mg/dl) 1.550 0.366 0.599–4.005
RA characteristics
 RA duration (years) 1.010 0.582 0.974–1.048
 HAQ 1.202 0.506 0.699–2.067
 DAS28 (CRP) 1.026 0.936 0.545–1.933
 SDAI 0.945 0.845 0.534–1.670
 CDAI 0.944 0.851 0.517–1.723
Comorbidity
 Cardiovascular disease 1.138 0.749 0.515–2.518
 Metabolic disease 1.283 0.542 0.576–2.856
 CKD 1.402 0.689 0.268–7.344
 Autoimmune disease 0.468 0.494 0.053–4.137
 Interstitial pneumonia 3.611 0.003 1.553–8.399
PPSV23 vaccination 0.849 0.656 0.414–1.743
Treatment
 PSL 1.081 0.846 0.492–2.375
 MTX 1.431 0.390 0.632–3.240
 TAC 0.712 0.552 0.232–2.182
 Biologics 0.664 0.307 0.302–1.458
  1. PPSV23 23-valent pneumococcal polysaccharide vaccine, CRP C-reactive protein, RA rheumatoid arthritis, HAQ Health Assessment Questionnaire Disability Index score, DAS28 Disease Activity Score 28, SDAI simplified disease activity index, CDAI clinical disease activity index, CKD chronic kidney disease, PSL prednisolone, MTX methotrexate, TAC tacrolimus, CI confidence interval